医药生物行业周报（3月第4周）：头部Biotech迎来盈利拐点-20260330

Investment Rating - The report indicates a positive outlook for the biotech sector, particularly highlighting the first-time profitability of leading biotech companies, suggesting a shift towards sustainable profitability in the industry [2][3]. Core Insights - The biotech sector has shown resilience, with a weekly increase of 1.56%, outperforming the Shanghai and Shenzhen 300 index, which decreased by 1.41% [3][8]. - Leading biotech companies, such as BeiGene and Innovent Biologics, achieved their first annual profitability in 2025, marking a transition from valuation-driven to performance-driven growth in the domestic biotech market [3][12]. - The NewCo model is evolving, as evidenced by the acquisition agreement between Ouro Medicines and Gilead Sciences, which could generate significant revenue for the involved parties [3][13]. Market Weekly Review - The pharmaceutical and biotech sector saw a weekly increase of 1.56%, outperforming the Shanghai and Shenzhen 300 index, which fell by 1.41% [3][8]. - Sub-sectors such as medical research outsourcing (6.12%), raw materials (5.34%), and chemical preparations (2.88%) led the gains, while blood products (-2.95%), vaccines (-2.36%), and offline pharmacies (-1.63%) lagged [3][9]. - Notable stock performances included Meinohua (40.7%), Wanbangde (38.8%), and Fuxiang Pharmaceutical (27.6%) with significant gains, while Koyuan Pharmaceutical (-19.9%), *ST Changyao (-18.2%), and Duorui Pharmaceutical (-15.6%) faced declines [3][11]. Industry News and Key Company Announcements - Significant events include the announcement by Dize Pharmaceutical regarding promising clinical trial results for its drug in treating advanced non-small cell lung cancer [12]. - Innovent Biologics reported a revenue of 13.042 billion yuan for 2025, a 38.4% increase year-on-year, with product revenue growing by 44.6% [12][13]. - The report highlights various companies' financial performances, including a 316.29 billion yuan revenue for Heng Rui Pharmaceutical, reflecting a 13.02% year-on-year growth [13][14].